Amgen Will Have Day In Court With Roche
This article was originally published in The Pink Sheet Daily
Executive Summary
The company also reports that sales of its TNF inhibitor Enbrel are “not meeting expectations.”
You may also be interested in...
Roche’s Mircera BLA Set Back Three Months For FDA Review Of New Data
Delay could affect Amgen’s timeline for a potential filing of a preliminary injunction in its case against Roche, slated for trial in September.
Roche’s Mircera BLA Set Back Three Months For FDA Review Of New Data
Delay could affect Amgen’s timeline for a potential filing of a preliminary injunction in its case against Roche, slated for trial in September.
Amgen’s “Anticompetitive Scheme” On EPO Should Be Invalidated By Court, Roche Says
Roche seeks monetary damages and a ruling that Amgen’s conduct regarding its “monopoly” on erythropoietin is unlawful in court filing.